JP2005538150A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538150A5
JP2005538150A5 JP2004531341A JP2004531341A JP2005538150A5 JP 2005538150 A5 JP2005538150 A5 JP 2005538150A5 JP 2004531341 A JP2004531341 A JP 2004531341A JP 2004531341 A JP2004531341 A JP 2004531341A JP 2005538150 A5 JP2005538150 A5 JP 2005538150A5
Authority
JP
Japan
Prior art keywords
activity
estrogen
dose
phase
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004531341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538150A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2003/001325 external-priority patent/WO2004019954A1/en
Publication of JP2005538150A publication Critical patent/JP2005538150A/ja
Publication of JP2005538150A5 publication Critical patent/JP2005538150A5/ja
Pending legal-status Critical Current

Links

JP2004531341A 2002-08-28 2003-08-28 エストロゲン補充療法 Pending JP2005538150A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40633102P 2002-08-28 2002-08-28
PCT/CA2003/001325 WO2004019954A1 (en) 2002-08-28 2003-08-28 Estrogen replacement regimen

Publications (2)

Publication Number Publication Date
JP2005538150A JP2005538150A (ja) 2005-12-15
JP2005538150A5 true JP2005538150A5 (enExample) 2006-10-12

Family

ID=31978284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004531341A Pending JP2005538150A (ja) 2002-08-28 2003-08-28 エストロゲン補充療法

Country Status (25)

Country Link
US (1) US8946198B2 (enExample)
EP (1) EP1539184B1 (enExample)
JP (1) JP2005538150A (enExample)
KR (1) KR20050059092A (enExample)
CN (1) CN1678324A (enExample)
AT (1) ATE345804T1 (enExample)
AU (1) AU2003264203A1 (enExample)
BR (1) BR0313921A (enExample)
CA (1) CA2495330A1 (enExample)
CY (1) CY1106019T1 (enExample)
DE (1) DE60309895T2 (enExample)
DK (1) DK1539184T3 (enExample)
ES (1) ES2277139T3 (enExample)
HR (1) HRP20050291A2 (enExample)
IL (1) IL166585A0 (enExample)
MX (1) MXPA05002294A (enExample)
NO (1) NO20051545L (enExample)
NZ (1) NZ538342A (enExample)
PL (1) PL374762A1 (enExample)
PT (1) PT1539184E (enExample)
RS (1) RS20050184A (enExample)
RU (1) RU2340345C2 (enExample)
UA (1) UA82851C2 (enExample)
WO (1) WO2004019954A1 (enExample)
ZA (1) ZA200501274B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016011801A (es) * 2014-03-12 2017-07-14 Warner Chilcott Co Llc Crema de estradiol de dosis baja.
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
WO2016210003A2 (en) 2015-06-22 2016-12-29 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US4900734A (en) * 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
AU630334B2 (en) * 1987-09-24 1992-10-29 Jencap Research Ltd. Hormone preparations for hormone replacement therapy and contraceptive method
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5382873A (en) * 1991-12-04 1995-01-17 U.S. Philips Corporation High-pressure discharge lamp with incandescing metal droplets
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DK0836506T4 (da) * 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US6506390B2 (en) * 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10100911A1 (de) * 2001-01-11 2002-08-01 Schering Ag Verfahren zur Hormonersatztherapie und dessen Darreichungsform

Similar Documents

Publication Publication Date Title
JP2005538150A5 (enExample)
RU2005108977A (ru) Схема восполнения эстрогена
CA2267743A1 (en) Low dose estrogen interrupted hormone replacement therapy
KR960001371B1 (ko) 폐경기 전의 여성용 혼합 제형 및 이를 포함하는 팩
AU2021262853B2 (en) Contraceptive compositions and methods for improved efficacy and modulation of side effects
JPH04290830A (ja) 避妊薬処方物
JP2010508275A5 (enExample)
JP2010248270A (ja) 避妊用の組成
PT99782A (pt) Processo de fabrico de contraceptivos orais de baixo teor em estrogenio
JP2004508398A5 (enExample)
RU2001117204A (ru) Трехфазный пероральный контрацептив
RU2009120528A (ru) Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла
RU96119957A (ru) Фармацевтический комбинированный препарат для гормональной контрацепции
KR970704450A (ko) 자궁내막증식증 또는 자궁평활근종을 치료하기 위한 프로게스테론 길항제 및 게스타겐의 용도(Use of a Progesterone Antagonist and of a Gestagen for the Treatment of Endometriosis or Leiomyomate Uteri)
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
JP2008540482A5 (enExample)
WO2002094281A1 (en) Means and method for hormonal contraception
JP2942560B2 (ja) エストロゲン欠乏症治療用組成物
US7569560B2 (en) Extended cycle multiphasic oral contraceptive method
JP2005530791A (ja) 結合型エストロゲンとトリメゲストンの組み合わせを用いたホルモン補充療法
TW200534860A (en) Multiphase product for contraception based on a natural oestrogen
JP2003535127A (ja) 低用量経口避妊薬用のスターターキット
CA2248841C (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
EP1462107A1 (en) Method of female contraception and kit for use in such method
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein